A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis.
作者信息
Baffa Maria Efenesia, Bianchi Leila, Venturini Elisabetta, Pimpinelli Nicola, Berti Samantha
机构信息
Department of Health Sciences, Section of Dermatology, University of Florence, Firenze, Italy.
Infectious Diseases Unit, Meyer Children's Hospital, IRCCS, Florence, Italy.
出版信息
Pediatr Dermatol. 2025 Jul-Aug;42(4):880-881. doi: 10.1111/pde.15862. Epub 2025 Jan 29.
Abstract
摘要
相似文献
1
A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis.一例接受度普利尤单抗治疗的重度特应性皮炎小儿患者合并肺结核
Pediatr Dermatol. 2025 Jul-Aug;42(4):880-881. doi: 10.1111/pde.15862. Epub 2025 Jan 29.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
4
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.中重度特应性皮炎患者从度普利尤单抗转换为阿布昔替尼治疗：JADE DARE研究中使用度普利尤单抗治疗后疗效的事后分析
Dermatol Ther (Heidelb). 2025 Feb;15(2):367-380. doi: 10.1007/s13555-024-01320-y. Epub 2025 Feb 4.
5
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis.
Clin Exp Allergy. 2025 Jul 15. doi: 10.1111/cea.70117.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎：一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
8
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis.12岁以下儿童中重度特应性皮炎全身治疗的真实世界治疗结果：特应性皮炎儿科研究的2年结果
J Am Acad Dermatol. 2025 Feb;92(2):242-251. doi: 10.1016/j.jaad.2024.09.046. Epub 2024 Oct 9.
9
Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.度普利尤单抗对特应性皮炎患者生活质量的影响：一项随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2025 Jun 10;16:1587977. doi: 10.3389/fphar.2025.1587977. eCollection 2025.
10
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
本文引用的文献
1
Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report.度普利尤单抗成功治疗大疱性类天疱疮合并亚急性血行播散型肺结核：一例报告
Skin Res Technol. 2024 Jul;30(7):e13847. doi: 10.1111/srt.13847.
2
Expert consensus on the systemic treatment of atopic dermatitis in special populations.特应性皮炎特殊人群系统治疗专家共识。
J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1135-1148. doi: 10.1111/jdv.18922. Epub 2023 Feb 8.
3
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.非洲和印度儿童中非重症结核病的更短治疗疗程。
N Engl J Med. 2022 Mar 10;386(10):911-922. doi: 10.1056/NEJMoa2104535.
4
A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis.一项新型联合应用度普利尤单抗治疗合并肺结核的重症难治性寻常型天疱疮：病例报告及 RNA-seq 分析。
Front Immunol. 2022 Feb 9;13:825796. doi: 10.3389/fimmu.2022.825796. eCollection 2022.
5
The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology.白细胞介素-13/白细胞介素-4受体α轴参与了结核病相关的病理过程。
J Pathol. 2014 Nov;234(3):338-50. doi: 10.1002/path.4399. Epub 2014 Aug 6.
Zotero 插件